Moritani Tatsuru, Usui Hayato, Morinaga Tadahiko, Sato Hideyuki, Onoue Satomi
Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Material and Advanced Technology Development Center, Innovation/R&D Division, RICOH Company, Ltd., 2-7-1 Izumi, Ebina 243-0460, Japan.
Pharmaceutics. 2023 Feb 8;15(2):571. doi: 10.3390/pharmaceutics15020571.
This study aimed to develop a cyclosporine A (CsA)-loaded ternary solid dispersion (tSD/CsA) to improve the storage stability of a solid dispersion (SD) system and the oral absorbability of CsA. Hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose acetate succinate (HPMCAS) were selected as carrier materials of tSD, and tSD/CsA was prepared with a fine droplet drying process, a powderization technology that employs an inkjet head. The physicochemical properties of tSD/CsA were evaluated in terms of morphology, storage stability, dissolution behavior, and mucoadhesive property. After the oral administration of CsA samples (10 mg-CsA/kg) to rats, the plasma concentration of CsA was monitored to estimate oral absorbability. tSD/CsA comprised uniform shriveled particles with a diameter of 3.4 mm and span factor of 0.4, which is a parameter to estimate the particle size distribution. Although HPC-based binary SD showed marked aggregation of the particles after storage under 40 °C/75% relative humidity, there were no significant aggregations of tSD/CsA, due to the relatively low hygroscopic property of HPMCAS. The pH-dependent release of CsA with improved dissolution was observed in tSD/CsA. In the in vitro mucoadhesive evaluation using a mucin disk, tSD/CsA exhibited a better mucoadhesive property than HPC-based SD, possibly leading to prolonged retention of tSD particles in the gastrointestinal tract after oral administration. Orally-dosed tSD/CsA in rats resulted in significantly improved oral absorption of CsA, as evidenced by a 27-fold higher bioavailability than amorphous CsA. tSD/CsA may be a promising dosage option to improve the storage stability of a SD system and the biopharmaceutical properties of CsA.
本研究旨在开发一种载环孢素A(CsA)的三元固体分散体(tSD/CsA),以提高固体分散体(SD)系统的储存稳定性和CsA的口服吸收性。选择羟丙基纤维素(HPC)和羟丙基甲基纤维素醋酸琥珀酸酯(HPMCAS)作为tSD的载体材料,并采用精细液滴干燥工艺(一种使用喷墨头的粉末化技术)制备tSD/CsA。从形态、储存稳定性、溶解行为和粘膜粘附性方面评估了tSD/CsA的物理化学性质。给大鼠口服CsA样品(10mg CsA/kg)后,监测CsA的血浆浓度以评估口服吸收性。tSD/CsA由直径为3.4mm、跨度因子为0.4的均匀皱缩颗粒组成,跨度因子是估计粒径分布的一个参数。尽管基于HPC的二元SD在40℃/75%相对湿度下储存后显示出明显的颗粒聚集,但由于HPMCAS的吸湿性相对较低,tSD/CsA没有明显的聚集现象。在tSD/CsA中观察到CsA具有pH依赖性释放且溶解得到改善。在使用粘蛋白圆盘的体外粘膜粘附性评估中,tSD/CsA表现出比基于HPC的SD更好的粘膜粘附性,这可能导致口服给药后tSD颗粒在胃肠道中的滞留时间延长。大鼠口服tSD/CsA后,CsA的口服吸收显著改善,其生物利用度比无定形CsA高27倍。tSD/CsA可能是一种有前景的剂型选择,可提高SD系统的储存稳定性和CsA的生物药剂学性质。